Investors - Eurocine Vaccines

Eurocine Vaccines is publically listed at Spotlight Stock Market XSAT, Sweden, with the ticker EUCI.

To be notified with news, sign up to our newsfeed =>

Legal Advisor is Lindahl and MCL.

Sedermera is our Financial Advisor.

Patent and Intellectual Property (IP) advisors are Zacco and AWA.

Warrant exercise TO 5, May 2024 /
Optionsinlösen TO 5, maj 2024

Warrants of series TO 5 can be exercised during the period 2 – 17 May 2024. One warrant gives the right to purchase one share in Eurocine Vaccines at 0.03 SEK.

An information folder has been produced in connection with the warrant exercise (in Swedish):
Information folder, Eurocine Vaccines warrant exercise, May 2024

The complete conditions for warrants of series TO 5 (in Swedish):
Villkor för teckningsoptioner serie TO 5

Extraordinary General Meeting 31 May 2024

Below follow documents related to the Extraordinary General Meeting on the 31 May 2024:

Notice (Kallelse, in Swedish).

Proposed Decisions (Fullständiga beslutsförslag, in Swedish)

Proxy Form (Fullmaktsformulär, in Swedish)

Extraordinary General Meeting 18 March 2024

Below follow documents related to the Extraordinary General Meeting on the 18 March 2024:

Notice (Kallelse, in Swedish)

Complete Proposed Decisions (Fullständiga beslutsförslag, in Swedish)

Proxy Form (Fullmaktsformulär, in Swedish)

Preferential Unit Issue / Företrädesemission

Eurocine Vaccines gästade Småbolagspodden / Eurocine Vaccines visited the Small Companies´ pod

I samband med den pågående företrädesemission så gästade Eurocine Vaccines vd Hans Arwidsson Småbolagspodden för att berätta mer om bolagets senaste strategiska förändring och utvecklingen av den terapeutiska vaccinkandidaten mot Herpes simplexvirus typ 2 (HSV-2). Lyssna på Eurocine Vaccines i Småbolagspodden !

In connection with the ongoing rights issue, Eurocine Vaccines CEO Hans Arwidsson visited the Småbolagspodden to tell more about the company’s latest strategic change and the development of the therapeutic vaccine candidate against Herpes simplex virus type 2 (HSV-2). Listen to Eurocine Vaccines in the Small Companies´ pod (in Swedish)!

Read the Memorandum and the Teaser!

Eurocine Vaccines AB publishes an Information Memorandum in connection with the Company´s preferential issue of units, up to cirka 7.5 MSEK before issue costs. The subscription period begins Tuesday 9 January 2024.

Eurocine Vaccines´ Memorandum 2024 (in Swedish)

Eurocine Vaccines´ Teaser – a short information brochure (in Swedish). Please read the Important information (Viktig information)!

Terms and conditions for warrants TO 5 – Villkor för teckningsoptioner TO 5 (in Swedish).

Annual General Meeting 29 December 2023

Below follow documents related to the Annual General Meeting on the 29 December 2023:

Notice (Kallelse, in Swedish)

Complete Proposed Decisions (Fullständiga beslutsförslag, in Swedish)

Presentation of proposed board director (Presentation av föreslagen ledamot, in Swedish)

Annual Report 2022-2023 (Årsredovisning 2022-2023, in Swedish)

Proxy Form (Fullmaktsformulär, in Swedish)

Preferential Share Issue

Eurocine Vaccines AB publishes an Information Memorandum in connection with the Company´s preferential issue of shares up to cirka 9,7 MSEK before issue costs, which subscription period begins Wednesday 2 August 2023.

Eurocine Vaccines´ Memorandum 2023 (in Swedish)

Supplementary Memorandum 7 August 2023 (Tilläggsmemorandum, in Swedish)